Fungal nail disease

New England Journal of Medicine

Volumn 360, Issue 20, 2009, Pages 2108-2116

  De Berker, David ^a  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMOROLFINE; CICLOPIROXOLAMINE; CORTICOSTEROID; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; KETOCONAZOLE; TERBINAFINE; TIOCONAZOLE; TROSYL; UNCLASSIFIED DRUG; ANTIFUNGAL AGENT; CICLOPIROX; NAPHTHALENE DERIVATIVE; PYRIDONE DERIVATIVE;

ARTICLE; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; COST BENEFIT ANALYSIS; DEBRIDEMENT; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FINGERNAIL ONYCHOMYCOSIS; FOOT CARE; FUNGUS IDENTIFICATION; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION RATE; LICHEN PLANUS; LIVER TOXICITY; MONOTHERAPY; ONYCHOMYCOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS; TOENAIL ONYCHOMYCOSIS; YELLOW NAIL SYNDROME; AGED; DIFFERENTIAL DIAGNOSIS; MALE; ORAL DRUG ADMINISTRATION; REVIEW; SKIN DISEASE; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; AGED; ANTIFUNGAL AGENTS; DEBRIDEMENT; DIAGNOSIS, DIFFERENTIAL; FOOT DERMATOSES; HUMANS; ITRACONAZOLE; MALE; NAPHTHALENES; ONYCHOMYCOSIS; PRACTICE GUIDELINES AS TOPIC; PYRIDONES;

EID: 65649104423     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcp0804878     Document Type: Article

References (41)

1. Ghannoum MA, Hajjeh RA, Scher R, et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol 2000;43:641-648
2. Elewski BE, Charif MA. Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. Arch Dermatol 1997;133:1172-1173
3. Svejgaard EL, Nilsson J. Onychomycosis in Denmark: prevalence of fungal nail infection in general practice. Mycoses 2004;47:131-135
4. Szepietowski JC, Reich A, Garlowska E, Kulig M, Baran E. Factors influencing coexistence of toenail onychomycosis with tinea pedis and other dermatomycoses: a survey of 2761 patients. Arch Dermatol 2006;142:1279-1284
5. Dupuy A, Benchikhi H, Roujeau JC, et al. Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ 1999;318:1591-1594
6. Drake LA, Patrick DL, Fleckman P, et al. The impact of onychomycosis on quality of life: development of an international onychomycosis-specific questionnaire to measure patient quality of life. J Am Acad Dermatol 1999;41:189-196
7. Elewski BE. The effect of toenail onychomycosis on patient quality of life. Int J Dermatol 1997;36:754-756
8. Gupta AK, Jain HC, Lynde CW, Macdonald P, Cooper EA, Summerbell RC. Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol 2000;43:244-248
9. Daniel CR III, Norton LA, Scher RK. The spectrum of nail disease in patients with human immunodeficiency virus infection. J Am Acad Dermatol 1992;27:93-97
10. Effendy I, Lecha M, Feuilhade de Chauvin M, Di Chiacchio N, Baran R. Epidemiology and clinical classification of onychomycosis. J Eur Acad Dermatol Venereol 2005;19:Suppl 1:8-12.
11. Lilly KK, Koshnick RL, Grill JP, Khalil ZM, Nelson DB, Warshaw EM. Cost-effectiveness of diagnostic tests for toenail onychomycosis: a repeated-measure, single-blinded, cross-sectional evaluation of 7 diagnostic tests. J Am Acad Dermatol 2006;55:620-626
12. Koshnick RL, Lilly KK, St Clair K, Finnegan MT, Warshaw EM. Use of diagnostic tests by dermatologists, podiatrists and family practitioners in the United States: pilot data from a cross-sectional survey. Mycoses 2007;50:463-469
13. Summerbell RC, Cooper E, Bunn U, Jamieson F, Gupta AK. Onychomycosis: a critical study of techniques and criteria for confirming the etiologic significance of nondermatophytes. Med Mycol 2005;43:39-59.
14. Denning DW, Evans EG, Kibbler CC, et al. Fungal nail disease: a guide to good practice (report of a Working Group of the British Society for Medical Mycology). BMJ 1995;311:1277-1281
15. Fletcher CL, Hay RJ, Smeeton NC. Onychomycosis: the development of a clinical diagnostic aid for toenail disease. Part I. Establishing discriminating historical and clinical features. Br J Dermatol 2004;150:701-705
16. Gupta AK, Lynde CW, Jain HC, et al. A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study. Br J Dermatol 1997;136:786-789
17. Zaias N, Tosti A, Rebell G, et al. Autosomal dominant pattern of distal subungual onychomycosis caused by Trichophyton rubrum. J Am Acad Dermatol 1996;34:302-304
18. Lauharanta J. Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly. Clin Exp Dermatol 1992;17:Suppl 1:41-43
19. Reinel D. Topical treatment of onychomycosis with amorolfine 5% nail lacquer: comparative efficacy and tolerability of once and twice weekly use. Dermatology 1992;184:Suppl 1:21-24
20. Hay RJ, Mackie RM, Clayton YM. Tioconazole nail solution - an open study of its efficacy in onychomycosis. Clin Exp Dermatol 1985;10:111-115
21. Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol 2000;43:Suppl:S70-S80.
22. Epstein E. Fungus-free versus disease-free nails. J Am Acad Dermatol 2004;50:151-152
23. Evans EG, Sigurgeirsson B. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. BMJ 1999;318:1031-1035
24. Warshaw EM, Fett DD, Bloomfield HE, et al. Pulse versus continuous terbinafine for onychomycosis: a randomized, double-blind, controlled trial. J Am Acad Dermatol 2005;53:578-584
25. Gupta AK, Gover MD, Lynde CW. Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. J Eur Acad Dermatol Venereol 2006;20:1188-1193
26. Baran R, Sigurgeirsson B, de Berker D, et al. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement. Br J Dermatol 2007;157:149-157
27. Tavakkol A, Fellman S, Kianifard F. Safety and efficacy of oral terbinafine in the treatment of onychomycosis: analysis of the elderly subgroup in Improving Results in ONychomycosis-Concomitant Lamisil and Debridement (IRON-CLAD), an open-label, randomized trial. Am J Geriatr Pharmacother 2006;4:1-13.
28. Sigurgeirsson B, Olafsson JH, Steinsson JB, Paul C, Billstein S, Evans EG. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective followup study. Arch Dermatol 2002;138:353-357
29. Heikkilä H, Stubb S. Long-term results in patients with onychomycosis treated with terbinafine or itraconazole. Br J Dermatol 2002;146:250-253
30. Cham PM, Chen SC, Grill JP, Jonk YC, Warshaw EM. Reliability of self-reported willingness-to-pay and annual income in patients treated for toenail onychomycosis. Br J Dermatol 2007;156:922-928
31. O'Sullivan DP, Needham CA, Bangs A, Atkin K, Kendall FD. Postmarketing surveillance of oral terbinafine in the UK: report of a large cohort study. Br J Clin Pharmacol 1996;42:559-565
32. Chambers WM, Millar A, Jain S, Burroughs AK. Terbinafine-induced hepatic dysfunction. Eur J Gastroenterol Hepatol 2001;13:1115-1118
33. Gupta AK, Ryder JE, Johnson AM. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol 2004;150:537-544
34. Gupta AK, Ryder JE, Baran R. The use of topical therapies to treat onychomycosis. Dermatol Clin 2003;21:481-489
35. Gupta AK. Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: a randomized, evaluator-blinded study. J Drugs Dermatol 2005;4:481-485
36. Baden HP. Treatment of distal onychomycosis with avulsion and topical antifungal agents under occlusion. Arch Dermatol 1994;130:558-559
37. Schram SE, Warshaw EM. Costs of pulse versus continuous terbinafine for ony chomycosis. J Am Acad Dermatol 2007;56:525-527
38. Warshaw EM, Foster JK, Cham PM, Grill JP, Chen SC. NailQoL: a quality-of-life instrument for onychomycosis. Int J Dermatol 2007;46:1279-1286
39. American Academy of Dermatology. Guidelines of care for superficial mycotic infections of the skin: onychomycosis. J Am Acad Dermatol 1996;34:116-121
40. Roberts DT, Taylor WD, Boyle J. Guidelines for treatment of onychomycosis. Br J Dermatol 2003;148:402-410
41. Seebacher C, Brasch J, Abeck D, et al. Onychomycosis. Mycoses 2007;50:321-327